121 related articles for article (PubMed ID: 29517632)
1. Clinical Significance of Histological Effect and Intratumor Stromal Expression of Tenascin-C in Resected Specimens After Chemoradiotherapy for Initially Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma.
Hayasaki A; Murata Y; Usui M; Hibi T; Ito T; Iizawa Y; Kato H; Tanemura A; Azumi Y; Kuriyama N; Kishiwada M; Mizuno S; Sakurai H; Yoshida T; Isaji S
Pancreas; 2018 Apr; 47(4):390-399. PubMed ID: 29517632
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression.
Kobayashi M; Mizuno S; Murata Y; Kishiwada M; Usui M; Sakurai H; Tabata M; Ii N; Yamakado K; Inoue H; Shiraishi T; Yamada T; Isaji S
Pancreas; 2014 Apr; 43(3):350-60. PubMed ID: 24622063
[TBL] [Abstract][Full Text] [Related]
3. Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoing Gemcitabine-Based Chemoradiotherapy.
Yamada R; Mizuno S; Uchida K; Yoneda M; Kanayama K; Inoue H; Murata Y; Kuriyama N; Kishiwada M; Usui M; Ii N; Tsuboi J; Tano S; Hamada Y; Tanaka K; Horiki N; Ogura T; Shiraishi T; Takei Y; Katayama N; Isaji S
Pancreas; 2016; 45(5):761-71. PubMed ID: 26784908
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?
Konstantinidis IT; Warshaw AL; Allen JN; Blaszkowsky LS; Castillo CF; Deshpande V; Hong TS; Kwak EL; Lauwers GY; Ryan DP; Wargo JA; Lillemoe KD; Ferrone CR
Ann Surg; 2013 Apr; 257(4):731-6. PubMed ID: 22968073
[TBL] [Abstract][Full Text] [Related]
5. Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma.
Leppänen J; Lindholm V; Isohookana J; Haapasaari KM; Karihtala P; Lehenkari PP; Saarnio J; Kauppila JH; Karttunen TJ; Helminen O; Huhta H
Pancreas; 2019 Jan; 48(1):43-48. PubMed ID: 30451798
[TBL] [Abstract][Full Text] [Related]
6. Survival impact on triple-modal strategy comprising hyperthermia, external radiation, and chemotherapy for unresectable locally advanced (UR-LA) pancreatic ductal adenocarcinoma.
Shimomura O; Oda T; Hashimoto S; Doi M; Hiroshima Y; Numajiri H; Takahashi K; Furuya K; Miyazaki Y; Owada Y; Ogawa K; Ohara Y; Hisakura K; Akashi Y; Enomoto T; Sakurai H
Surg Oncol; 2021 Jun; 37():101542. PubMed ID: 33740629
[TBL] [Abstract][Full Text] [Related]
7. Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized Pancreatic Ductal Adenocarcinoma, With Special Attention to Initially Locally Advanced Unresectable Tumor.
Takeuchi T; Mizuno S; Murata Y; Hayasaki A; Kishiwada M; Fujii T; Iizawa Y; Kato H; Tanemura A; Kuriyama N; Azumi Y; Usui M; Sakurai H; Isaji S
Pancreas; 2019 Feb; 48(2):281-291. PubMed ID: 30629019
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.
Massucco P; Capussotti L; Magnino A; Sperti E; Gatti M; Muratore A; Sgotto E; Gabriele P; Aglietta M
Ann Surg Oncol; 2006 Sep; 13(9):1201-8. PubMed ID: 16955382
[TBL] [Abstract][Full Text] [Related]
9. The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy with combined resection of portal vein following preoperative chemoradiotherapy.
Jaseanchiun W; Kato H; Hayasaki A; Fujii T; Iizawa Y; Tanemura A; Murata Y; Azumi Y; Kuriyama N; Kishiwada M; Mizuno S; Usui M; Sakurai H; Isaji S
Pancreatology; 2019 Mar; 19(2):307-315. PubMed ID: 30738764
[TBL] [Abstract][Full Text] [Related]
10. Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival.
Kadera BE; Sunjaya DB; Isacoff WH; Li L; Hines OJ; Tomlinson JS; Dawson DW; Rochefort MM; Donald GW; Clerkin BM; Reber HA; Donahue TR
JAMA Surg; 2014 Feb; 149(2):145-53. PubMed ID: 24306217
[TBL] [Abstract][Full Text] [Related]
11. Stromal Palladin Expression Is an Independent Prognostic Factor in Pancreatic Ductal Adenocarcinoma.
Sato D; Tsuchikawa T; Mitsuhashi T; Hatanaka Y; Marukawa K; Morooka A; Nakamura T; Shichinohe T; Matsuno Y; Hirano S
PLoS One; 2016; 11(3):e0152523. PubMed ID: 27023252
[TBL] [Abstract][Full Text] [Related]
12. Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis.
Mataki Y; Kurahara H; Idichi T; Tanoue K; Hozaka Y; Kawasaki Y; Iino S; Maemura K; Shinchi H; Ohtsuka T
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801465
[TBL] [Abstract][Full Text] [Related]
13. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
[TBL] [Abstract][Full Text] [Related]
14. Highly aligned stromal collagen is a negative prognostic factor following pancreatic ductal adenocarcinoma resection.
Drifka CR; Loeffler AG; Mathewson K; Keikhosravi A; Eickhoff JC; Liu Y; Weber SM; Kao WJ; Eliceiri KW
Oncotarget; 2016 Nov; 7(46):76197-76213. PubMed ID: 27776346
[TBL] [Abstract][Full Text] [Related]
15. Tenascin-C expression and its prognostic significance in oral and pharyngeal squamous cell carcinoma.
Atula T; Hedström J; Finne P; Leivo I; Markkanen-Leppänen M; Haglund C
Anticancer Res; 2003; 23(3C):3051-6. PubMed ID: 12926160
[TBL] [Abstract][Full Text] [Related]
16. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D Supplementation is a Promising Therapy for Pancreatic Ductal Adenocarcinoma in Conjunction with Current Chemoradiation Therapy.
Mukai Y; Yamada D; Eguchi H; Iwagami Y; Asaoka T; Noda T; Kawamoto K; Gotoh K; Kobayashi S; Takeda Y; Tanemura M; Mori M; Doki Y
Ann Surg Oncol; 2018 Jul; 25(7):1868-1879. PubMed ID: 29675761
[TBL] [Abstract][Full Text] [Related]
18. Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic adenocarcinoma but not in UICC-T4.
Murata Y; Mizuno S; Kishiwada M; Hamada T; Usui M; Sakurai H; Tabata M; Inoue H; Shiraishi T; Isaji S
Pancreas; 2012 Jan; 41(1):130-6. PubMed ID: 21934551
[TBL] [Abstract][Full Text] [Related]
19. Tenascin C in the Tumor-Nerve Microenvironment Enhances Perineural Invasion and Correlates With Locoregional Recurrence in Pancreatic Ductal Adenocarcinoma.
Furuhashi S; Sakaguchi T; Murakami T; Fukushima M; Morita Y; Ikegami K; Kikuchi H; Setou M; Takeuchi H
Pancreas; 2020 Mar; 49(3):442-454. PubMed ID: 32132519
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic ductal adenocarcinoma.
Murata Y; Mizuno S; Kishiwada M; Uchida K; Noguchi D; Gyoten K; Hayasaki A; Fujii T; Iizawa Y; Tanemura A; Kuriyama N; Sakurai H; Isaji S
Pancreatology; 2021 Dec; 21(8):1482-1490. PubMed ID: 34452821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
